top of page

No-Exam Term Life Insurance With Multiple Sclerosis: What Typically Triggers Extra Review

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Multiple sclerosis can vary widely from person to person. Because of that, many accelerated/no-exam programs won't finalize instantly and instead require a fuller underwriting review.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

MS: Usually Not "Instant," but Not Always "Impossible"

Diagnosis type and stability over time (flare pattern and recency)

Functional impact (work status, mobility limits, disability)

Medication history and specialist follow-up consistency

Multiple sclerosis is a chronic autoimmune condition affecting the central nervous system, and underwriters approach it with considerably more nuance than a simple approve-or-decline decision based on the diagnosis label alone. The specific MS subtype is the first variable underwriters want to establish, because relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS) represent fundamentally different disease trajectories with different mortality implications. RRMS - the most common form, affecting approximately 85% of people initially diagnosed with MS - involves discrete relapses followed by periods of partial or full recovery, which means functional stability between episodes is achievable and documented. PPMS and SPMS, by contrast, involve ongoing neurological deterioration without the recovery periods characteristic of RRMS, which presents a materially higher long-term mortality concern to underwriting teams. Because instant underwriting algorithms cannot assess these distinctions in depth, MS cases almost always require full individual underwriting review rather than automated approval through an accelerated platform.

Underwriters evaluate MS-related disability through functional questions that closely map to the Expanded Disability Status Scale (EDSS), even when they never reference the EDSS by name in their application questions. The EDSS assesses eight functional domains: pyramidal (motor), cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and ambulation. Carrier application forms ask about walking ability without assistive devices, coordination, vision disturbances, bladder and bowel control, cognitive function, and activities of daily living - answers to these questions construct a functional profile equivalent to an EDSS assessment. An applicant who is fully ambulatory, driving independently, employed full-time, and experiencing no significant functional limitations occupies a meaningfully different underwriting position than one who requires a cane, has reduced hand coordination, or has experienced bladder dysfunction. Providing recent neurologist visit notes that explicitly address each of these functional domains in clinical language gives underwriters the most complete and favorable picture of current status.

One underwriting factor that consistently surprises applicants is that being on a disease-modifying therapy (DMT) is viewed as a positive signal rather than a negative one by most experienced underwriters. DMT use - whether interferon beta-1a, natalizumab, ocrelizumab, dimethyl fumarate, or newer oral agents like siponimod - demonstrates that a board-certified neurologist has evaluated the disease and determined that active pharmacological intervention is clinically warranted. It also demonstrates that the applicant is engaged in their own care, adhering to specialist recommendations, and being monitored through the regular follow-up that most DMTs require. Carriers evaluating MS cases prefer seeing an actively managed, monitored diagnosis over an untreated one precisely because management reduces the uncertainty that drives adverse underwriting decisions. Stable adherence to a single DMT without meaningful medication changes over the past 12 to 24 months correlates with disease stability, which underwriters weight positively when constructing a rating.

There is an important and underappreciated distinction between a carrier postponing a life insurance application and declining it outright, and understanding this difference significantly affects how applicants should plan their timeline. A postponement typically communicates that the carrier is interested in the risk but wants to see 12 to 24 more months of stable follow-up data - meaning no new relapses, no significant functional decline, no major DMT changes, and no hospitalizations related to MS - before committing to a decision. This is not a permanent door closing; it is a structured request for additional evidence of stability, after which the application can be resubmitted with the updated documentation. Contrast this with a decline, which reflects a determination that the risk falls outside the carrier's appetite under current guidelines and may require a longer elapsed time, a change in clinical circumstances, or a different carrier relationship before the application is viable.

Some carriers will consider stable RRMS applicants at Standard or mildly substandard table ratings, particularly when the application file is built to tell a cohesive, well-documented story of managed stability. The combination of factors that produces the most favorable outcome typically includes documented specialist follow-up every three to six months, no clinical relapses in the preceding two or more years, continued full-time employment in a role not requiring physical labor, an established and stable DMT regimen, and neurologist records that explicitly confirm functional independence. A strong application does not just list the diagnosis and current medications - it presents a narrative arc from initial diagnosis through current management that demonstrates a consistently stable and actively overseen condition. Working with a broker who has placed MS cases across multiple carriers, rather than applying through a single direct online portal, substantially improves the likelihood of identifying the specific carrier whose underwriting guidelines best align with an individual applicant's clinical profile.

For the main term life overview and how no-exam underwriting works (and when cases move to traditional review), see: https://www.careproinsurance.com/instant-term-life-insurance

For general information only; consult appropriate professionals for legal, tax, or medical advice. Preliminary pricing from a quote may differ from the final terms in your issued policy.

Frequently Asked Questions

Can I get no-exam term life insurance with multiple sclerosis?

Sometimes. Many accelerated/no-exam programs are restrictive with MS, but other underwriting paths may be available depending on stability and severity. Guidelines vary and underwriting applies.

Why do instant programs often screen out MS?

Because MS severity varies and carriers usually need more context (stability, function, meds) than an automated track can evaluate quickly.

What MS details do underwriters usually ask about?

Common focus areas include diagnosis type, time since last flare, symptom stability, work/disability status, medications, and specialist follow-up. Requirements vary by carrier.

Will I need a medical exam with MS?

Not always, but additional documentation is common. Requirements depend on the carrier, coverage amount, and your medical history.

How can I avoid wasting applications with MS history?

Be consistent and specific about stability, meds, and functional impact. A targeted approach is usually better than submitting multiple "instant" applications that get paused.

Does the type of MS - RRMS versus PPMS or SPMS - affect underwriting outcomes differently?

Yes, the MS subtype is one of the first things underwriters want to establish. RRMS (relapsing-remitting) is the most favorable from an underwriting standpoint because it involves discrete relapses with periods of stability or recovery, and the majority of RRMS patients maintain substantial function for many years. PPMS (primary progressive) and SPMS (secondary progressive) both involve ongoing neurological decline by definition, which presents a higher long-term risk profile with less predictable stability. Carriers that will consider RRMS at Standard or mildly substandard table ratings may postpone or decline PPMS and SPMS cases pending longer documented stability or more detailed functional assessment.

Do carriers look at my EDSS score when underwriting my MS application?

Most carriers don't ask for a formal EDSS score, but the functional questions in their applications map closely to the eight domains the EDSS measures - walking, coordination, vision, bladder function, cognition, and more. In practice, recent neurologist visit notes that address each of these domains will answer the underwriter's questions. Providing comprehensive specialist records that document current functional status across all EDSS domains, rather than just confirming a diagnosis, gives the underwriter the clearest possible picture and reduces the chance of a postponement due to incomplete functional information.

Is being on a disease-modifying therapy seen as a red flag by life insurance underwriters?

No - in most cases, DMT use is viewed as a positive signal. It tells the underwriter that a specialist is actively monitoring your condition, that you are engaged in your own care, and that your neurologist has determined your disease warrants pharmacological management. An unmonitored MS diagnosis with no treatment record is typically harder to evaluate favorably than one with consistent specialist visits and a stable, documented DMT regimen. Stable adherence to a single therapy without recent dose changes or medication switches is one of the stronger favorable data points in an MS application file.

Get Covered With The Right Plan

MS often requires more context than an instant track can gather. This page explains what underwriters usually look for and how to avoid wasted applications.

Explore term life options

bottom of page